Tillomed Malta Limited Pharmaceutical Import Profile — Malta (DGFT 2022–2026)

Name: Tillomed Malta Limited Pharmaceutical Import Records from India — 4 Products, $3.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Tillomed Malta Limited — Pharmaceutical Importer Profile (2026) | 4 Products, $3.3M Trade | TransData Nexus

Tillomed Malta Limited

Pharmaceutical Importer · Malta · Advanced Oncology Focus · $3.3M Total Trade · DGFT Verified

Tillomed Malta Limited is a pharmaceutical importer based in Malta with a total trade value of $3.3M across 4 products in 2 therapeutic categories. Based on 107 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Tillomed Malta Limited sources from 5 verified Indian suppliers, with Emcure Pharmaceuticals Limited accounting for 72.2% of imports.

Tillomed Malta Limited — Import Portfolio & Supplier Network

Tillomed Malta Limited import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Tillomed Malta Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Emcure Pharmaceuticals Limited	$1.3M	71	72.2%
Maiva Pharma Private Limited	$198.5K	12	11.1%
Msn Laboratories Private Limited	$177.2K

What Formulations Does Tillomed Malta Limited Import?

Formulation	Value	Ships
Medicines melphalan 50 MG powder &diluent INJ-zentiva - poland batch no cp230014 manufacturing sep 2023 exp aug	$100.0K	4
Medicines combi Pack of melphalan hydrochloride for injection 50 MG/vial (lyophilized) & sterile diluent for	$100.0K	4
Medicines melphalan 50 MG wt 2.5 ML filinj wt sleeve-esmias batch no. cp230016 manufacturing sep 2023 exp aug	$92.7K	2
Medicines melphalan 50 MG pow. and SOL.INJ 2.5ML fill - it batch no cp230015 manufacturing sep 2023 exp aug	$87.2K	2
Medicines treprostinil INJ.50MG/20ML tillo fr sn : batch no. : es240103a mfg: apr 2024 exp: mar	$54.8K	2
Medicines treprostinil INJ.100MG/20ML tillo fr sn: batch no. :es240048a mfg: mar 2024 exp: jan	$54.8K	2
Medicines treprostinil INJ.50MG/20ML tillo fr sn : batch no. :es220091f mfg: apr 2022 exp: mar	$50.3K	2
Medicines tranex 500MG tabs 2x10t uhlmann tillo-de batch no h231739b manufacturing sep-2023 exp	$50.0K	1
Trientine 167MG capsules- 1x100 cap Each hard gelatin capsule contains- trientine dihydrochloride 250MG- batch	$50.0K	1
Cuivrin 167MG capsules- 1x100 cap eachhard gelatin capsule contains- trientinedihydrochloride 250MG- batch	$50.0K	1
Carglumic acid 200MG tablets 12x5t grbatch no h232553c mfg nov -2023exp	$50.0K	1
Medicines amphotericin b liposomalfor INJ.50 MG : batch no. :es240138a mfg: apr 2024 exp: mar	$50.0K	2
Cabazitaxel 60 MG for SOL x 1	$50.0K	1
Azacitadine vial 100MG x 1	$50.0K	1
Azacitadine lyo 100MG tillomed	$50.0K	1

Tillomed Malta Limited imports 59 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Melphalan	Advanced Oncology	$1.2M	50	5.8%	4
2	Carmustine	Advanced Oncology	$1.1M	23	5.1%	3
3	Amphotericin	Antifungals	$600.0K	12	0.7%	12
4	Busulfan	Advanced Oncology	$297.6K	22	4.8%	6

Tillomed Malta Limited imports 4 pharmaceutical products across 2 categories into Malta totaling $3.3M.

Tillomed Malta Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Tillomed Malta Limited is a pharmaceutical importer based in Malta, specializing in the procurement of finished pharmaceutical formulations from India. The company operates as a subsidiary of Tillomed Laboratories Ltd., a UK-based pharmaceutical firm that focuses on the development, licensing, and marketing of generic pharmaceuticals. Tillomed Laboratories Ltd. is owned by Emcure Pharmaceuticals Ltd., one of India's leading pharmaceutical companies.

In Malta, Tillomed Malta Limited plays a significant role in the pharmaceutical distribution network, supplying a range of generic medicines to hospitals, wholesalers, and pharmacies. The company's product portfolio encompasses various therapeutic areas, including oncology and antifungal treatments. By importing high-quality generic pharmaceuticals, Tillomed Malta Limited contributes to the accessibility and affordability of essential medicines within the Maltese healthcare system.

2Distribution Network

Tillomed Malta Limited's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Malta. The company operates a central warehouse located in Paola, a town in the South Eastern Region of Malta. This facility is equipped to handle a diverse range of pharmaceutical products, including those requiring ambient or cold chain storage conditions.

The logistics capabilities of Tillomed Malta Limited are tailored to meet the specific needs of the pharmaceutical industry, ensuring compliance with Good Distribution Practice (GDP) guidelines. The company's geographic coverage extends throughout Malta, supplying medicines to various healthcare providers, including hospitals, pharmacies, and wholesalers. While the primary focus is on the Maltese market, the company's affiliation with Tillomed Laboratories Ltd. and Emcure Pharmaceuticals Ltd. suggests potential access to broader distribution networks within the European Union.

3Industry Role

In Malta's pharmaceutical supply chain, Tillomed Malta Limited functions primarily as a pharmaceutical importer and distributor. The company sources finished pharmaceutical formulations from Indian manufacturers and supplies them to local healthcare providers. This role is crucial in ensuring the availability of generic medicines, particularly in therapeutic areas such as oncology and antifungal treatments. By importing these products, Tillomed Malta Limited enhances the diversity and affordability of the pharmaceutical market in Malta.

The company's operations are characterized by a focus on quality assurance and regulatory compliance. Tillomed Malta Limited adheres to the Medicines Authority's guidelines, ensuring that all imported medicinal products meet the required standards for safety, efficacy, and quality. (medicinesauthority.gov.mt) This commitment underscores the company's integral role in maintaining the integrity and reliability of Malta's pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Tillomed Malta Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Tillomed Malta Limited's sourcing strategy exhibits a high degree of concentration, with a significant majority of its pharmaceutical imports originating from India. The company's total import value from India amounts to $3.3 million USD, encompassing 107 shipments across four products in two therapeutic categories. This sourcing pattern indicates a strategic focus on leveraging India's robust pharmaceutical manufacturing capabilities, particularly in the production of generic medicines.

The top five products imported by Tillomed Malta Limited include Melphalan, Carmustine, Amphotericin, and Busulfan, with Melphalan and Carmustine accounting for substantial portions of the import value. This concentration suggests a targeted approach to fulfilling specific therapeutic needs within the Maltese market. The reliance on a limited number of products may streamline procurement processes and strengthen supplier relationships.

However, the high concentration in sourcing raises potential risks related to supply chain disruptions. Any challenges faced by Indian suppliers, such as regulatory changes, production issues, or logistical constraints, could impact the availability of these critical medicines in Malta. To mitigate such risks, it is advisable for Tillomed Malta Limited to consider diversifying its supplier base and exploring alternative sourcing options.

2Supply Chain Resilience

Importing Pharmaceuticals into Malta — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Malta

1Regulatory Authority & Framework

In Malta, the Medicines Authority serves as the primary regulatory body overseeing the importation, distribution, and marketing of medicinal products. The authority is responsible for ensuring that all pharmaceutical products meet the required standards for safety, efficacy, and quality. This includes the enforcement of Good Manufacturing Practice (GMP) guidelines, which are essential for maintaining the integrity of the pharmaceutical supply chain. (medicinesauthority.gov.mt)

Key legislation governing pharmaceutical imports into Malta includes the Medicines Act, 2003, and relevant EU Directives. These regulations stipulate the requirements for obtaining marketing authorizations, conducting GMP inspections, and ensuring compliance with quality standards. The Medicines Authority conducts GMP inspections to assess compliance with EU GMP Guidelines, as specified in the provisions of the Medicines Act, 2003, and relevant EU Directives. (medicinesauthority.gov.mt)

For Indian pharmaceutical companies seeking to export to Malta, understanding and adhering to these regulatory frameworks is crucial. This includes ensuring that manufacturing processes comply with EU GMP standards and obtaining the necessary marketing authorizations from the Medicines Authority. By aligning with Malta's regulatory requirements, Indian exporters can facilitate smoother market entry and establish trustworthy partnerships with importers like Tillomed Malta Limited.

2Import Licensing & GMP

Frequently Asked Questions — Tillomed Malta Limited

What products does Tillomed Malta Limited import from India?

Tillomed Malta Limited imports 4 pharmaceutical products across 2 categories. Top imports: Melphalan ($1.2M), Carmustine ($1.1M), Amphotericin ($600.0K), Busulfan ($297.6K).

Who supplies pharmaceuticals to Tillomed Malta Limited from India?

Tillomed Malta Limited sources from 5 verified Indian suppliers. The primary supplier is Emcure Pharmaceuticals Limited (72.2% of imports, $1.3M).

What is Tillomed Malta Limited's total pharmaceutical import value?

Tillomed Malta Limited's total pharmaceutical import value from India is $3.3M, based on 107 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Tillomed Malta Limited focus on?

Tillomed Malta Limited imports across 2 categories. The largest: Advanced Oncology (81.6%), Antifungals (18.4%).

Get Full Tillomed Malta Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.